HBPCF (Helix BioPharma) 50-Day SMA: $1.72 (As of Jun. 30, 2026)


HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma 50-Day SMA?

Helix BioPharma HBPCF 28 50-Day SMA is $1.72 as of Jun. 30, 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100.

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2026-06-30), Helix BioPharma's 50-Day SMA is $1.72. It's 20-Day SMA is $1.71 and 200-Day SMA is $1.57.

Helix BioPharma  (OTCPK:HBPCF) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.

Helix BioPharma 50-Day SMA Related Terms

HBPCF vs VRTX, REGN, ALNY: 50-Day SMA Comparison

For the Biotechnology subindustry, Helix BioPharma's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helix BioPharma 50-Day SMA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's 50-Day SMA falls into.


HBPCF
28GF Score
Helix BioPharma Corp HBPCF
50-Day SMA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma  (OTCPK:HBPCF) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 50-Day SMA →
What does a 50-Day SMA of $1.72 mean?
Helix BioPharma (HBPCF) has a 50-Day SMA of $1.72 as of Jun. 30, 2026. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Helix BioPharma and its competitors.
Is Helix BioPharma's 50-Day SMA too high?
Helix BioPharma's current 50-Day SMA is $1.72. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's 50-Day SMA compare to VRTX and REGN?
Helix BioPharma's 50-Day SMA of $1.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 50-Day SMA for a Biotechnology company?
A good 50-Day SMA depends on the Biotechnology industry context. However, 50-Day SMA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 50-Day SMA mean?
A high 50-Day SMA can signal that a stock is expensive relative to its fundamentals. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current 50-Day SMA is $1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current 50-Day SMA of $1.72. The current 50-Day SMA is $1.72. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 50-Day SMA calculated?
50-Day SMA is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current 50-Day SMA is $1.72 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

50-Day SMA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price